Ann: INV043 With ICI Therapy Achieved 80% Tumour Control For ASCC, page-2

INV043 DRAMATICALLY IMPROVED IMMUNE CHECKPOINT INHIBITOR EFFECTIVENESS WHEN
USED IN COMBINATION, ACHIEVING ~80% TUMOUR CONTROL IN PRECLINICAL STUDIES
Highlights:
 Topically applied INV043 in combination with an immune checkpoint inhibitor (ICI)
resulted in ~80% of subjects being tumour-free. The study was conducted by Peter Mac
using immune competent anal squamous cell carcinoma (ASCC) in vivo models
 ICIs, the standard of care for the treatment of several cancers, are a class of
immunotherapy drug. Despite widespread clinical use as a monotherapy, ICI
effectiveness is typically limited to a small proportion of patients
 Results support previous findings by Hudson Institute using intratumorally administered
INV043 in combination with ICIs on another cancer type (triple negative breast cancer)
 Opens additional treatment options for upcoming clinical trial programs that span
multiple cancers
 ASCC has potential to be designated as an orphan indication – leading to an expedited
regulatory approval process
 The findings reinforce the potential for collaboration partnerships using combination
therapies to extend the patent life of blockbuster ICIs
 Global ICI market forecast to grow at 16.8% CAGR to reach US$189 billion by 20321


Sadly they didn't mention the ICI, but imagine if it was KEYTRUDA. Merck would be making an offer straight away.

Anyway, that's a cracker anns.

Should touch 1c tomorrow at least.

GLTA